CAR-NK plus PD-1 for anaplastic thyroid cancer
Part of Cancer clinical trials.
This trial tests a new treatment for anaplastic thyroid cancer that combines two immune-based therapies: NKG2D CAR-NK cells (a type of white blood cell engineered to attack cancer) and a PD-1 inhibitor (a drug that helps the immune system fight cancer). The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with anaplastic thyroid cancer and have at least one tumor that can be measured and is at least 1 cm in size.
- Your liver and kidney function are good enough to handle the treatment.
- You are able to cooperate with the treatment plan and follow-up visits.
- You do not have other serious health conditions, including other types of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is comparing two different ways of giving radiation therapy for anaplastic and poorly differentiated thyroid cancer. The goal is to see which method is more effective in treating the cancer.
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This Phase 1 study tests a lab-made immune cell treatment (CAR-NK92 cells) for people with solid tumors that have not responded to earlier treatments. The goal is to see how safe it is and whether it can shrink tumors or help control cancer.
Hear when a new Anaplastic Throid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.